Zydus Life gains on USFDA nod for heart drug

Zydus Lifesciences jumped 2 percent on December 1 after the pharma player received the final nod from the US Food and Drug Administration for a heart drug.

Ivabradine reduces the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.

At 1.15 pm, Zydus Lifesceiences was trading at Rs 640.7 on the NSE, up 0.53 percent from the previous session’s closing price.

Ivabradine is also used in children aged 6 months and older for the treatment of stable symptomatic heart failure due to cardiomyopathy. The drug will be manufactured at the company’s formulation facility in Ahmedabad.

Follow our market blog to catch all the live updates

“Zydus was one of the first abbreviated new drug application (ANDA) applicants to submit a substantially complete ANDA with a paragraph IV certification for Ivabradine Tablets, 5 mg and 7.5 mg and therefore may be eligible for 180 days of shared generic exclusivity for Ivabradine Tablets, 5 mg and 7.5 mg,” said Zydus Life in a filing with the bourses.

The stock has gained 52.5 percent this year against Nifty’s 11.42 rise percent during the period.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Get ₹100 cashback on checking your free Credit Score on Moneycontrol. Gain valuable financial insights in just two clicks! Click here